The following virtual Satellite Symposium is an industry-sponsored, presentation offered in conjunction with the 2022 Highlights of ASH in North America (HOA). There is no fee to attend and registration to HOA is not required to participate. This event is not part of the official ASH meeting program and is planned solely by the sponsoring companies.
Conversations and Commentaries®: Translating Evolving Data for the Use of BTK Inhibitors in CLL Into Clinical Practice
Thursday, March 17, 2022, at 5:00 – 6:30 p.m. Eastern time
This symposium is CME-certified and will be presented LIVE at the date and time above.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and has a highly variable clinical course. Members of the oncology care team need to be aware of prognostic factors influencing treatment decisions. Regimens include multiple single-agent small-molecule inhibitors, but the use of anti-CD20 monoclonal antibodies and oral oncolytics in combination is rapidly progressing the current treatment paradigm. Oncology pharmacists, physicians, and nurses are well positioned to manage patients and educate other health care professionals about adverse effects of immunotherapeutic options. Further consideration will be given to how members of the oncology care team can facilitate access to current and emerging agents and alleviate the economic burden associated with treatment for patients. This 90 minute program will mix evidence-based presentations with case-based discussion to prepare physicians, nurses, and pharmacists involved in the care of patients with CLL to recommend appropriate therapies for patients and navigate the changing landscape of CLL treatment.
Managing Company: Physicians' Education Resource, LLC
Contact: [email protected]
Please contact Kelly Cade, ASH Grants and Satellite Symposia Manager, Consultant, at [email protected]